Sophia genetics and illumina sign co-marketing agreement to speed adoption of next-generation sequencing (ngs) in clinical diagnostics

LAUSANNE, Switzerland – 13 September 2016 – Sophia Genetics, the global leader in Data-Driven Medicine (DDM), announced today that it has entered into a co-marketing agreement with Illumina, the global leader in DNA sequencing technology. The two companies will co-market their respective products and solutions to accelerate the adoption of next-generation DNA Sequencing (NGS) technologies by hospitals and laboratories for patients’ clinical diagnosis. Under the agreement, the two parties will kick-off the collaboration with joint marketing programs in EMEA.

Jurgi Camblong, CEO and co-founder of Sophia Genetics said, “We are very pleased to enter into this agreement with Illumina to speed the adoption of NGS in clinical diagnostics. Today’s agreement with Illumina underlines the value of state-of-the-art analytical solutions in routine diagnostics which truly unlock the promises of data-driven medicine for patients around the world.”

The new co-marketing arrangement will first cover the EMEA region, where Sophia Genetics and Illumina will help more hospitals and laboratories engaged in diagnostics transition to NGS and rapidly get faster, easier and more accurate results for their patients’ clinical diagnosis.